Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks’ Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies. J of Skin [Internet]. 2018 Feb. 23 [cited 2025 Apr. 19];2(S1):S16. Available from: https://skin.dermsquared.com/skin/article/view/307